ArticleVirology journal2026
An epidemiological survey of HPV infection among women in Southern Hebei, China.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the genotypes and distribution patterns of human papillomavirus (HPV) infections among women in southern Hebei, China.
methodsCervical specimens were collected from female clinical patients (including both outpatients and inpatients) and health examination participants at Handan Central Hospital between September 2022 and August 2025. HPV genotyping was performed using a real-time fluorescent PCR method with the HybriBio (Chaozhou, China) 23-type HPV nucleic acid genotyping kit (fluorescent PCR), which detects 23 HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 6, 11, 42, 43, 44, 53, 66, 73, 81, 82). The study analyzed the positivity rates of each genotype, the proportion and genotype distribution among different age groups and cervical diseases.
resultsAmong 41,045 cervical samples, the HPV positivity rate was 24.20%. The top three most prevalent genotypes were 52, 16, and 58, respectively. The detection rate of high-risk HPV (hrHPV) was 20.22%, while that of low-risk HPV (lrHPV) was 7.40%. The positivity rates were highest among women aged <20 (40.27%), >60 (29.30%), and 51-60 years (28.00%), monotypic infections were predominant across all age groups, and the positivity rates were significantly higher among patients with cervical intraepithelial neoplasia and cervical cancer compared to the general population.
conclusionThis study on HPV genotype distribution among women in the southern Hebei region provides strong evidence for establishing a cervical cancer screening and prevention system in the area, as well as valuable epidemiological data for the development and application of HPV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.